| Question 1: The landmaark work relating NTCP to dose distributions in the image based treatment planning era (3DCRT era) that historically preceded current efforts such as HyTEC was published in: |
| Reference: | Emami B, et al, Tolerance of normal tissue to therapeutic irradiation, IJROBP 1991;21:109-12 Grimm J, Marks LB, Jackson A et al, High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview, IJROBP 2021; 110: 1-10. |
| Choice A: | 1940 |
| Choice B: | 1963 |
| Choice C: | 1991 |
| Choice D: | 1998 |
| Choice E: | 2010 |
| Question 2: The HyTEC project Red Journal issue provides: |
| Reference: | Reference: Grimm J, Marks LB, Jackson A et al, High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview, IJROBP 2021; 110: 1-10; especially Tables 2 and 3 |
| Choice A: | Only NTCP guidelines for hypofractionated radiation therapy based on analyses of published, peer reviewed clinical studies. |
| Choice B: | Only NTCP guidelines for conventionally fractionated radiation therapy based on national randomized clinical trials. |
| Choice C: | Both NTCP and TCP guidelines for hypofractionated radiation therapy based on analysis of published, peer reviewed clinical studies. |
| Choice D: | NTCP and TCP guidelines for hypofractionated radiation therapy based on the experiences of the members of the WGSBRT. |
| Choice E: | Both NTCP and TCP guidelines for brachytherapy based on analysis of published, peer reviewed clinical studies. |
| Question 3: The dose axis in most of the HyTEC paper mathematical models is most often: |
| Reference: | Reference: See the 16 TCP and NTCP site-specific articles in the HyTEC issue: International Journal of Radiation Oncology Biology Physics Vol 110 (1), May 2021 |
| Choice A: | Fractionation-corrected (modified to account for the total dose and number of fractions); several radiobiological models are used in different papers |
| Choice B: | Purely physical dose |
| Choice C: | Given in terms of RBE |
| Choice D: | Fractionation corrected only with the universal survival curve. |
| Choice E: | Always given by mean organ or tumor dose. |
| Question 4: SBRT is a desirable form of radiation therapy for pancreatic cancer because: |
| Reference: | Reference: Mahadevan A, Moningi S, Grimm J, et al. , Maximizing tumor control and limiting complications with stereotactic body radiation therapy for pancreatic cancer, IJROBP 2021; 110 : 206-216. |
| Choice A: | A short treatment schedule interferes minimally with chemotherapy. |
| Choice B: | A short treatment schedule interferes minimally with surgery. |
| Choice C: | Short treatment schedules are more compatible with respiratory motion management. |
| Choice D: | Short treatment schedules are more compatible with constant risk-organ positions. |
| Choice E: | The SBRT total doses are low. |
| Question 5: All the following features of published studies made it difficult to synthesize their data into coherent sbrt outcomes models except: |
| Reference: | International Journal of Radiation Oncology Biology Physics 2021; 110: all organ-specific papers
Jackson A, Marks LB, Bentzen SM, et al , The Lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome, IJROBP 2010; 76 (3S), S155-S160. |
| Choice A: | Lack of individual patient dose-volume histograms associated with a particular outcome |
| Choice B: | Lack of community-wide agreement on how a given risk organ should be segmented for treatment planning and dose evaluation. |
| Choice C: | Lack of community-wide agreement regarding complication and tumor control endpoints. |
| Choice D: | Adherence to standards for reporting |
| Question 6: Clinicians can best view the HyTEC guidelines expressed in the TCP and NTCP papers as: |
| Reference: | Reference: Grimm J, Marks LB, Jackson A et al, High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview, IJROBP 2021; 110: 1-10. |
| Choice A: | Ground truth as of 2021 |
| Choice B: | Works in progress based on analysis of literature selected by the authors of the HyTEC paper after search of available peer-reviewed publications. |
| Choice C: | Dose-response models based on mechanistic descriptions of the organ or tumor. |
| Choice D: | The best results of modern randomized controlled national trials. |
| Choice E: | The result of comparing Kaplan-Meier and competing risks models for each endpoint. |
